slides · global inventory
Image
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 119,566
Current window 91,651-91,680
Pages 3,986
Rows per page 30
Component
91,651-91,680 of 119,566
12
The slide uses a high-quality photograph of a Tiffany & Co. store interior as the background.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations 1 hit
14
The slide serves as a section divider or speaker introduction.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
17
LVMH | Results Presentation Deck | 31 slidesLVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Satisfaction1 hit
29
The slide features a high-fashion photograph of a woman with a Louis Vuitton handbag, likely used as a stylistic transition or section break.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations 1 hit
01
The background image appears to be a microscopic view of chromosomes or cellular structures, reinforcing the 'telomere' focus.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
02
MAIA Biotechnology | Investor Presentation Deck | 31 slidesMAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
03
The slide outlines the status of THIO-101, 102, and 103, highlighting FDA designations and clinical trial progress.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · The Ask1 hit
04
The slide uses a custom timeline/pipeline layout to show drug development stages.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
05
MAIA Biotechnology | Investor Presentation Deck | 31 slidesMAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
07
This is a transition or thesis slide emphasizing competitive differentiation.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
Slide highlights a strategic partnership/traction milestone.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
14
The slide uses a specific medical study to justify a change in clinical trial endpoint strategy.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
21
The slide presents two line charts showing tumor volume over time, illustrating the efficacy of THIO in primary treatment and rechallenge scenarios.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
23
MAIA Biotechnology | Investor Presentation Deck | 31 slidesMAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
24
The slide highlights both regulatory exclusivity (NCE) and a multi-layered patent strategy extending into the 2040s.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
26
The slide contrasts the massive combined market of established CPIs ($42B) with the smaller market share of Libtayo ($0.5B) to frame the opportunity for partnership/growth.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
29
MAIA Biotechnology | Investor Presentation Deck | 31 slidesMAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
31
The slide shows a biological mechanism of action (MOA) validation using TIFs as a biomarker.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
01
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
02
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
04
The slide contrasts the company's decentralized approach against centralized CLIA lab competitors.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
07
The slide outlines the technical workflow from sample collection to diagnostic output.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
09
The slide features a minimalist design with a corporate logo and a halftone dot pattern.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
10
The slide uses a visual timeline/process flow to show disease progression.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
16
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
23
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
24
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
03
The slide uses a two-column layout to contrast a specific lead asset (MAT2203) with broader pipeline opportunities.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
04
The slide uses a combination of molecular diagrams and bulleted benefits to explain the LNC technology.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit